Bravecto Plus is a drug owned by INTERVET, INC. It is protected by 4 US drug patents filed from 2025 to 2031. Out of these, 2 patents are active and 2 patents have expired. Details of Bravecto Plus’s patents and their expiration are given below.
Exclusivity Information
Bravecto Plus holds 1 exclusivity out of which 1 has expired. Details of Bravecto Plus's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCI | Nov 14, 2022 |
About Bravecto Plus
Bravecto Plus is a drug
owned by INTERVET, INC.
Bravecto Plus uses
Fluralaner, Moxidectin as the active
ingredients.
Active Ingredient:
Bravecto Plus uses
Fluralaner,
Moxidectin
as the active ingredients.
Check out other Drugs and Companies using
Fluralaner, Moxidectin ingredient.